Table 2.
Group | (TL) 8th day (s) | (TL) 9th day (s) | IR |
---|---|---|---|
Vehicle control (saline) | 35.05 ± 3.17 | 30.96 ± 2.64 | 0.132 ± 0.288 |
Scopolamine (0.4 mg/kg) | 60.74 ± 2.27 | 66.67 ± 0.76 | 0.88 ± 0.028 |
MBPL (200 mg/kg) + Scopolamine | 55.36 ± 1.37∗∗ | 50.3 ± 0.99∗∗ | 0.1 ± 0.073 |
MBPL (400 mg/kg) + Scopolamine | 50.5 ± 1.34∗∗ | 43.67 ± 1.69∗∗ | 0.156 ± 0.10 |
MGPB (200 mg/kg) + Scopolamine | 53.12 ± 1.3∗ | 45.67 ± 1.85∗∗ | 0.163 ± 0.061 |
MGPB (400 mg/kg) + Scopolamine | 39.16 ± 2.69∗∗ | 32.75 ± 1.89∗∗ | 0.194 ± 0.2147 |
Shankhpushpi + Scopolamine | 36.16 ± 2.51∗∗ | 27.83 ± 2.1∗∗ | 0.299 ± 0.141 |
Piracetam (100 mg/kg) + Scopolamine | 26.12 ± 2.6∗∗ | 21.78 ± 1.19∗∗ | 0.19 ± 0.611 |
MBPL and MGBP at both tested doses significantly reversed memory impairments induced by Scopolamine and are comparable to that of both controls. MGPD (400 mg/kg) exhibited the best memory-enhancing activity among all test samples, with minimum transfer latency time. All the data are calculated as average ± SD; n = 6. Data are statistically effective at ∗p < 0.05 and highly effective at ∗∗p < 0.005 in comparison to Scopolamine.